Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Chinese Tech Stocks CCP Paranoia and Best AI Tech Stocks ETF - 26th Oct 21
Food Prices & Farm Inputs Getting Hard to Stomach - 26th Oct 21
Has Zillow’s Collapse Signaled A Warning For The Capital Markets? - 26th Oct 21
Dave Antrobus Welcomes Caribou to Award-Winning Group Inc & Co - 26th Oct 21
Stock Market New Intermediate uptrend - 26th Oct 21
Investing in Crypto Currencies With Both Eyes WIDE OPEN! - 25th Oct 21
Is Bitcoin a Better Inflation Hedge Than Gold? - 25th Oct 21
S&P 500 Stirs the Gold Pot - 25th Oct 21
Stock Market Against Bond Market Odds - 25th Oct 21
Inflation Consequences for the Stock Market, FED Balance Sheet - 24th Oct 21
To Be or Not to Be: How the Evergrande Crisis Can Affect Gold Price - 24th Oct 21
During a Market Mania, "no prudent professional is perceived to add value" - 24th Oct 21
Stock Market S&P500 Rallies Above $4400 – May Attempt To Advance To $4750~$4800 - 24th Oct 21
Inflation and the Crazy Crypto Markets - 23rd Oct 21
Easy PC Upgrades with Motherboard Combos - Overclockers UK Unboxing - MB, Memory and Ryzen 5600x CPU - 23rd Oct 21
Gold Mining Stocks Q3 2021 - 23rd Oct 21
Gold calmly continues cobbling its Handle, Miners lay in wait - 23rd Oct 21
US Economy Has Been in an Economic Depression Since 2008 - 22nd Oct 21
Extreme Ratios Point to Gold and Silver Price Readjustments - 22nd Oct 21
Bitcoin $100K or Ethereum $10K—which happens first? - 22nd Oct 21
This Isn’t Sci-Fi: How AI Is About To Disrupt This $11 Trillion Industry - 22nd Oct 21
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Natus Medical Justifies Recent Run With Record Q3 Results

Companies / BioTech Oct 24, 2014 - 05:57 PM GMT

By: Submissions

Companies

Nicholas Maithya writes: Natus Medical (NASDAQ:BABY) is up more than 125% over the last twelve months and based on recent results, that run seems fully justified with room left for more. The stock closed at $33.51 on Thursday 23, up 2.16% for the day following its impressive results released on the previous day.


However, the most notable part is that the company has been on a rally since mid-October last year. On October 14, 2013, the stock closed at $14.88, but the price is now up more than 125% to $33.51 per share. The stock price seems to suggest that the buyers are dominating the market, with the fast stochastic RSI already pegged at 100, while the slow stochastic RSI is just above 61. This may suggest that there could be a short-term pullback for the stock, but long-term outlook remains bullish.

Chart via Quantshare.com

Natus Medical, which provides neurodiagnostic and newborn care products and services across the globe, uses new age technology to execute its business. The company has experienced sequential growth over the last three quarters in the process topping $1 billion in market valuation.

Natus Medical Q3 Earnings in Focus

On Wednesday 22nd, Natus Medical reported record Q3 non-GAAP EPS of $0.33 a 10 percent increase from last year’s $0.30 diluted non-GAAP EPS. The company also reported 5 percent increase in revenue to $89.9 million compared to $85.4 million reported in Q3, 2013. GAAP net income also increased significantly to $7.8 million or $0.24 per share compared to last year’s $6.3 million or $0.20 per share.

The company’s revenues were boosted by improved economic conditions in North America, while Europe continued to dwindle. During the company’s earnings conference, the company’s CEO, James B. Hawkins expressed that Grass acquisition is likely to affect the overall margins for 2013, since the newly acquired unit has lower margins compared to the parent Natus Medical.

Natus Medical is on course to reporting close to $1.00 per share in GAAP net income based on the current run-rate. The company reported $0.67 per share in GAAP net income for the three months ended September 30, 2014. Natus’ recent quarter GAAP EPS of $0.24 per share puts it closer to achieving the $1.00 GAAP EPS target for the current year.  On the other hand, Analysts expect a non-GAAP EPS of $1.24.

The company leadership was optimistic following a quarter that delivered record results on both top line and bottom line, as well as, a significant organic growth.

"I am very pleased with our third quarter results as we achieved record revenues and earnings. Both revenue and earnings exceeded the top end of guidance. I am most satisfied with our 63% gross profit margin as well as recording over 5% organic revenue growth. Consistent organic revenue growth and improving margins have been major goals for Natus in 2014 and our results demonstrate significant progress to the achievement of these goals," said Jim Hawkins, President and Chief Executive Officer of the Company.

Valuation

Natus Medical trades at 36.19x price to earnings ratio for the trailing 12-months, while the forward PE for period ended Dec 2015 is estimated at 23.61x. The forward P/E ratio values the stock at about $33.52 based on the 2015-estimated non-GAAP EPS of $1.42 per share.

Therefore, the stock appears to be valued at par. However, a year ago, analysts had estimated an EPS of $1.05 for the company for year 2014. Since then, this estimate has been revised upwards as they currently expect it to post $1.24 non-GAAP EPS this year.

This means that we cannot rule out upward revisions in the coming quarters, which could raise the current EPS estimates for 2015. Furthermore, based on the promise depicted by the company’s recent performances, Natus Medical has the ability to continue trading at current P/E ratio of 36x or at least 30x for the next twelve months. This means that the stock could possibly rise to trade at about $40-$50 per share during that period.

Just 8 years into the market, Natus now has the largest neurodiagnostic and service organization in the world. The nature in which the industry is growing can only promise upside returns in the future, which has drawn a lot of optimism from the management. A huge market share and growing margins will spur the company’s growth in the next few years.

The Risks

Overall, Natus Medical is not one of the biggest companies (in term of financial muscle) out there, and faces competition from the likes of Johnson & Johnson (NYSE:JNJ), a renowned global brand in biotechnology and pharmaceuticals. Johnson &Johnson is a mega-cap company, and this is gigantic compared to Natus Medical’s $1.05 billion in market valuation.

JNJ is a potential threat to Natus in terms of market share retention. If the industry continues to grow rosier, then JNJ, given its financial muscle, could potentially launch similar or better products compared to what Natus currently offers.

Conclusion

Natus Medial’s recent rally is well justified and based on Q3 results, as well as, the results for the last nine months; the company seems well poised for more growth in the coming quarters. In just over 12 months, Natus has doubled in value, rewarding investors with massive capital returns. Expectations show that this growth is likely to continue, with earnings expected to grow by a double-digit figure in the next few years.

By Nicholas Maithya

Financial analyst by profession with extensive experience in investment reseacrh and stock market analysis. I am currently a published author at Seeking Alpha, and a writer at Quantshare.Com, a trading software company.

© 2014 Copyright Nicholas Maithya - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in